Bajaj Healthcare Limited Earnings Summary — Q1 FY2027
Bajaj Healthcare Posts Strong Profit Growth Amid Revenue Expansion and Discontinued Operations
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue grew 8.2% sequentially in Q1 FY2027.
- Revenue of ₹166 Cr is 11.3% higher year-on-year.
- Revenue has compounded at 9.9% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹14 Cr is 15.8% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 45.2% annualised across the period.
- Operating margin stands at 17.4% in Q1 FY2027.
- Operating margin expanded by 89 bps year-on-year.
- Over the last two years operating margin has contracted by 117 bps.
- PBT margin is 9.8%.
- Expense growth of 10.1% remained below revenue growth of 11.3%.
- Operating profit of ₹29 Cr is 17.3% higher year-on-year.
- Operating leverage continues to improve.
- 5 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 69/100 (Healthy) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 166 | 153 | 161 | 148 | 149 | 154 | 123 | 133 | 132 | 134 |
| Expenses | Stable | 137 | 130 | 131 | 121 | 124 | 143 | 101 | 109 | 108 | 118 |
| Operating Profit | Improving | 29 | 23 | 31 | 27 | 25 | 12 | 22 | 25 | 25 | 16 |
| Operating Margin | Volatile | 17.4% | 14.8% | 19.0% | 18.2% | 16.5% | 7.6% | 17.6% | 18.4% | 18.5% | 12.0% |
| Other Income | Volatile | 1 | -34 | 1 | 0 | 1 | 13 | -1 | 4 | -0 | -36 |
| Interest | Stable | 6 | 6 | 6 | 6 | 5 | 6 | 6 | 8 | 8 | 6 |
| Depreciation | Stable | 7 | 8 | 7 | 7 | 6 | 8 | 7 | 7 | 7 | 7 |
| Profit Before Tax | Volatile | 16 | -24 | 19 | 15 | 14 | 11 | 8 | 14 | 9 | -33 |
| Tax | Volatile | 3 | -1 | 3 | 4 | 2 | 0 | -3 | 4 | 2 | -3 |
| Net Profit | Volatile | 14 | -23 | 16 | 11 | 12 | 11 | 12 | 9 | 7 | -30 |
| Net Margin | Volatile | 8.3% | -14.9% | 9.7% | 7.5% | 8.0% | 7.2% | 9.5% | 7.1% | 5.4% | -22.4% |
Key Takeaways
- Revenue from continuing operations grew 11.28% YoY to ₹16,563.17 Lakhs, reflecting steady demand in the pharmaceutical segment.
- The company reported a sharp turnaround in Net Profit compared to the previous quarter (Q4 FY2026), which was severely impacted by a one-time reversal of technical know-how income.
- Operating performance improved significantly, with Profit Before Tax from continuing operations rising to ₹1,645.83 Lakhs from ₹1,452.51 Lakhs in the same period last year.
- Losses from discontinued operations narrowed significantly to ₹19.48 Lakhs from ₹34.00 Lakhs YoY as the company continues to divest non-core assets.
- Capital structure improved following the conversion of 2,079,409 warrants into equity shares, raising total paid-up capital to ₹1,683.13 Lakhs.
- Management has successfully utilized ₹19,324.32 Lakhs from the recent preferential issue for loan repayments and capital expenditure.
- The acquisition of Genrx Pharmaceuticals Private Limited remains pending NCLT approval and has not yet been consolidated into financial results.
Management Guidance
Management is focused on the effective implementation of the Genrx acquisition pending NCLT approval and continues to streamline the business by divesting units classified as discontinued operations.
Sentiment Shift
Improving
The company has recovered from the one-time income reversal that caused a loss in the previous quarter, showing improved operational efficiency and a cleaner balance sheet after loan repayments.
Outlook
The outlook remains optimistic as the company transitions toward higher-value products and higher capacity utilization following major debt reductions. The successful integration of Genrx Pharmaceuticals will be a key growth driver once NCLT approvals are finalized.
From the Annual Report (Key Quotes)
“The Company has identified only one reportable segment i.e. Pharmaceuticals.”
“The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for... Repayment of loan [₹15,000 Lakhs].”
“The total value of assets classified as held for sale represents lower of carrying value or fair value.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Bajaj Healthcare Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.